Zobrazeno 1 - 10
of 834
pro vyhledávání: '"SINGLE-CHAIN DIABODY"'
Autor:
Duranti, Claudia, Lastraioli, Elena, Iorio, Jessica, Capitani, Chiara, Carraresi, Laura, Gonnelli, Leonardo, Arcangeli, Annarosa
Publikováno v:
In Protein Expression and Purification August 2021 184
Autor:
Lu, Li, Liu, Ningbo, Fan, Kaihu, Zhang, Guojing, Li, Chuan, Yan, Yongjia, Liu, Tong, Fu, Wei-Huahua
Publikováno v:
In Molecular Immunology May 2019 109:149-156
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
In Journal of Controlled Release 10 March 2015 201:56-67
Autor:
Chen, Min, Wen, Kai, Tao, Xiaoqi, Xie, Jie, Wang, Limiao, Li, Yang, Ding, Shuangyang, Jiang, Haiyang
Publikováno v:
In Protein Expression and Purification August 2014 100:19-25
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Chen, Min1 (AUTHOR), Wen, Kai1 (AUTHOR), Tao, Xiaoqi2 (AUTHOR), Ding, Shuangyang1 (AUTHOR), Xie, Jie1 (AUTHOR), Yu, Xuezhi1 (AUTHOR), li, Jiancheng1 (AUTHOR), Xia, Xi1 (AUTHOR), Wang, Yang1 (AUTHOR), Xie, Sanlei1 (AUTHOR), Jiang, Haiyang1 (AUTHOR) haiyang@cau.edu.cn
Publikováno v:
Food Additives & Contaminants. Part A: Chemistry, Analysis, Control, Exposure & Risk Assessment. Dec2014, Vol. 31 Issue 12, p1959-1967. 9p. 4 Charts, 6 Graphs.
Publikováno v:
In Journal of Biological Chemistry 18 September 2009 284(38):25612-25619
Autor:
Kashentseva, Elena A., Douglas, Joanne T., Zinn, Kurt R., Curiel, David T., Dmitriev, Igor P.
Publikováno v:
In Journal of Molecular Biology 2009 388(3):443-461
Autor:
Krakow J; Maverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA., Hammel M; Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA., Zhu Y; Maverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA., Hillier BJ; Maverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA., Paolella B; Maverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA., Desmarais A; Maverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA., Wall R; Maverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA., Chen TT; Maverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA., Pei R; Maverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA., Karunatilake C; Maverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA., DuBridge R; Maverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA., Vinogradova M; Maverick Therapeutics, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Brisbane, CA, USA.
Publikováno v:
Antibody therapeutics [Antib Ther] 2021 Dec 16; Vol. 5 (1), pp. 1-10. Date of Electronic Publication: 2021 Dec 16 (Print Publication: 2022).